Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 19;14(6):1576.
doi: 10.3390/cancers14061576.

Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer

Kohei Mori  1 , Kazumasa Matsumoto  1 , Noriyuki Amano  1 , Dai Koguchi  1 , Soichiro Shimura  1 , Masahiro Hagiwara  1 , Yuriko Shimizu  1 , Masaomi Ikeda  1 , Yuichi Sato  1 , Masatsugu Iwamura  1
Affiliations

Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer

Kohei Mori et al. Cancers (Basel). .

Abstract

Objective: To investigate the relationship between clinicopathological findings and membranous CD155 (mCD155) or cytoplasmic CD155 (cCD155) expression in bladder cancer (BC). Methods: We retrospectively analyzed 103 patients with BC who underwent radical cystectomy between 1990 to 2015 at Kitasato University Hospital. Immunohistochemical staining was performed to evaluate CD155 expression in tumor cells. Cases with > 10% expression on the membrane or cytoplasm of tumor cells were positive. The Fisher′s exact test was used for categorical variables and the Kaplan−Meier method was used for survival outcomes. Univariate and multivariate Cox regression hazard models were used to evaluate the survival risk factors. Results: Cases that were mCD155-positive were associated with high-grade tumors (p = 0.02), nodal status (p < 0.01), and pT stage (p = 0.04). No association with any clinicopathological factor was observed in the cCD155 cases. Kaplan−Meier analysis showed that mCD155-positive cases had shorter periods of recurrence-free survival (p = 0.015) and cancer-specific survival (p = 0.005). Only nodal status was an independent predictor for both cancer-specific survival and recurrence-free survival in multivariate analysis (p = 0.02 and p < 0.01, respectively). Conclusion: mCD155 expression may be a marker of an aggressive phenotype and a poor prognosis in patients with BC.

Keywords: CD155; bladder cancer; cystectomy; immunohistochemistry; poliovirus receptor; urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CD155 expression in non-neoplastic urothelial cells and urothelial carcinoma. (A) No or weak staining was observed in the non-neoplastic urothelial cell; (B) negative staining; (C) cytoplasmic staining; (D) membranous staining in urothelial carcinoma cells (original magnification, 400×).
Figure 1
Figure 1
CD155 expression in non-neoplastic urothelial cells and urothelial carcinoma. (A) No or weak staining was observed in the non-neoplastic urothelial cell; (B) negative staining; (C) cytoplasmic staining; (D) membranous staining in urothelial carcinoma cells (original magnification, 400×).
Figure 2
Figure 2
Probability of survival in patients with urothelial carcinoma of the bladder according to mCD155 expression estimated using the Kaplan–Meier method. (A) Cancer-specific survival; (B) recurrence-free survival.
Figure 2
Figure 2
Probability of survival in patients with urothelial carcinoma of the bladder according to mCD155 expression estimated using the Kaplan–Meier method. (A) Cancer-specific survival; (B) recurrence-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Antoni S., Ferlay J., Soerjomataram I., Znaor A., Jemal A., Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur. Urol. 2017;71:96–108. doi: 10.1016/j.eururo.2016.06.010. - DOI - PubMed
    1. Matsumoto K., Tabata K., Hirayama T., Shimura S., Nishi M., Fujita T., Iwamura M. Robot-assisted laparoscopic radical cystectomy is a safe and effective procedure for patients with bladder cancer compared to laparoscopic and open surgery: Perioperative outcomes of a single-center experience. Asian J. Surg. 2019;42:189–196. doi: 10.1016/j.asjsur.2017.11.002. - DOI - PubMed
    1. Xylinas E., Cha E.K., Sun M., Rink M., Trinh Q.D., Novara G., Green D.A., Pycha A., Fradet Y., Daneshmand S., et al. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br. J. Cancer. 2012;107:1826–1832. doi: 10.1038/bjc.2012.464. - DOI - PMC - PubMed
    1. Oughton J.B., Poad H., Twiddy M., Collinson M., Hiley V., Gordon K., Jhonson M., Jain S., Noon A.P., Chahal R., et al. Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): A protocol for a randomised controlled feasibility study. BMJ Open. 2017;7:e017913. doi: 10.1136/bmjopen-2017-017913. - DOI - PMC - PubMed